T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.

Pharmaceutical

T3D Therapeutics

John Didsbury

David Keim

Jessica Stanek

Hoda Gabriel

Blake Swearingen

Stan Chamberlain

Warren Strittmatter

The Leadership Team at T3D Therapeutics is responsible for steering the company's strategic direction, overseeing the development of T3D-959, and ensuring alignment between scientific research and clinical objectives. Comprising top executives with expertise in science and medicine, they drive innovation and decision-making to advance breakthrough therapies for Alzheimer's disease.

Leadership Team

Advisory and Consulting

Leadership Team

About

Team members

Other teams at T3D Therapeutics

Advisory and Consulting